Separately, Oppenheimer reissued an “outperform” rating and issued a $14.00 price target on shares of Moleculin Biotech in a research report on Monday, July 18th.
Moleculin Biotech Trading Down 0.6 %
Shares of NASDAQ:MBRX opened at $1.70 on Friday. The stock has a market capitalization of $48.58 million, a PE ratio of -2.70 and a beta of 1.78. Moleculin Biotech has a 1 year low of $1.02 and a 1 year high of $3.20. The firm has a fifty day moving average price of $1.58 and a 200 day moving average price of $1.55.
Institutional Trading of Moleculin Biotech
Several hedge funds and other institutional investors have recently bought and sold shares of MBRX. Sigma Planning Corp acquired a new stake in Moleculin Biotech in the 4th quarter worth about $80,000. Renaissance Technologies LLC increased its position in Moleculin Biotech by 79.3% during the 1st quarter. Renaissance Technologies LLC now owns 59,900 shares of the company’s stock worth $107,000 after purchasing an additional 26,500 shares in the last quarter. Walker Asset Management LLC bought a new stake in Moleculin Biotech during the 2nd quarter worth approximately $32,000. Finally, State Street Corp grew its holdings in Moleculin Biotech by 19.2% during the 1st quarter. State Street Corp now owns 71,397 shares of the company’s stock worth $127,000 after acquiring an additional 11,497 shares during the last quarter. Institutional investors and hedge funds own 10.57% of the company’s stock.
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.
- Get a free copy of the StockNews.com research report on Moleculin Biotech (MBRX)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.